https://www.avient.com/sites/default/files/2023-03/AVNT Q2 2022 Earnings Presentation - Website Version.pdf
Global Compact & fulfilled Communication of Progress (COP) requirements • New Sustainability Strategy overview page including our 2022 AIP ESG metrics • New ESG Performance page with ESG ratings, awards, and certifications • Increased disclosures on carbon emissions, including disclosure of Climate Change Scenario Analysis • Added new Product Stewardship and Chemical Management policies • Enhanced data reporting for Workforce Demographics • Improved social disclosures on human rights, dependent care and special leave and strategic training management 2021 SUSTAINABILITY REPORT Launching integrated sustainability website in parallel with report Aligned with leading reporting frameworks 9 ESG PERFORMANCE & AWARDS 10 84th ENVIRONMENTAL SOCIAL GOVERNANCE 2 1 3 (as of 6/30/22) 2022 O U TLO O K $429 $490 2021 2022E $3.05 $3.50 2021 2022E FY 2022 GUIDANCE (TOTAL COMPANY: CURRENT PORTFOLIO) 12 Sales Adjusted Operating Income $4,819 $5,100 2021 2022E + 6% Adjusted EPS + 14% + 15% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 20% excluding FX) 13 CASH FLOW / LEVERAGE ($ millions) 2022E Cash Flow from Operating Activities 400$ Less: Run-Rate CapEx (90) CapEx for Clariant Integration (10) CapEx for IT System Upgrade (15) Total CapEx (115) Free Cash Flow 285$ Adjusted EBITDA 635$ Net Debt / Adjusted EBITDA 1.6x 14 DYNEEMA / DISTRIBUTION UPDATES • Strong performance so far in 2022 in-line with our modeling • Acquisition to be finalized as early as September 1, pending standard regulatory process and closing conditions • Encouraging interest thus far from potential buyers for world-class business with a strong track record • Second round bids due in August DISTRIBUTION 15 PRO FORMA MODELING UPDATE 2022E ($M) Revenue 5,100$ 415$ 5,515$ (1,635)$ 3,880$ Adjusted EBITDA 635 130 765 (109) 656 EBITDA % 12% 31% 14% 7% 17% Adj.
D I S T R IBU T I O N) 18 END-MARKET FOCUS FOR NEW INNOVATION Semiconductors Robotics Healthcare Interconnected disruptive markets with massive innovation needs 19 APPENDIX Performance Additives 15% Pigments 13% TiO2 11% Dyestuffs 3%Polyethylene 12% Nylon 6% Polypropylene 5% Other Raw Materials 30% Styrenic Block Copolymer 5% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials 22 • Significant raw material price inflation and tight inventory continued in Q2 2022, although at a slightly lesser rate compared to the prior quarter o For Q2 2022, the average cost of key hydrocarbon based materials was up 15%, roughly the same as the average cost of non- hydrocarbon based materials. • Continued supply chain challenges persisted during Q2 related to raw material spot purchases, freight constraints and productivity loss as a result of these shortages.
Annual Purchases RAW MATERIAL AND SUPPLY CHAIN UPDATE Based on 2021 purchases, excludes Distribution business SEGMENT DATA U.S. & Canada 50% EMEA 25% Asia 16% Latin America 9% 2021 SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 23% Packaging 19% Industrial 16% Building and Construction 10% Telecommunications 4% Energy 2% END MARKET REVENUE (1) Total company sales and adjusted EBITDA of $4,819M and $581M, respectively, include intercompany sales eliminations and corporate costs $2,402M $409M $919M $164M $1,631M $94M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $581M$4,819M (1) Transportation 11% Healthcare 15% 24 Packaging 34% Consumer 21% Healthcare 8% Industrial 16% Building & Construction 10% Transportation 9% Energy 1% Telecommunications 1% C O L O R , A D D I T I V E S & I N K S 2021 REVENUE | $2 .4 BILL ION US & Canada 32% EMEA 40% Asia 21% Latin America 7% END MARKET REGION 25 All charts reflect 2021 financials S P E C I A LT Y E N G I N E E R E D M AT E R I A L S Consumer 27% Healthcare 10% Packaging 7% Telecommunications 16% Transportation 11% Industrial 11% Building & Construction 11% Energy 7% 2021 REVENUE | $919 MILLION END MARKET US & Canada 55% EMEA 25% Asia 20% REGION 26 All charts reflect 2021 financials D I S T R I BU T I O N Healthcare 26% Consumer 23% Packaging 5% Industrial 20% Transportation 16% Building and Construction 8% Energy 1% Telecommunications 1% US & Canada 80% Asia 3% Latin America 17% END MARKET REGION K E Y S U P P L I ER S 2021 REVENUE | $1 .6 B ILL ION 27 All charts reflect 2021 financials TOTA L C O M PA N Y R E G I O N A L S A L E S BY END MARKET Packaging 30% Consumer 26%Healthcare 13% Industrial 14% Building & Construction 5% Telecommunications 2% Energy 2% Asia (16% of sales) Transportation 8% Packaging 32% Consumer 13% Healthcare 5% Industrial 17% Building & Construction 12% Telecommunications 5% Energy 4% EMEA (25% of sales) Transportation 12% 28 Consumer 25% Healthcare 19% Packaging 10% Industrial 17% Building & Construction 10% Telecommunications 4% Energy 2% US & Canada (50% of sales) Transportation 13% Packaging 38% Consumer 33% Healthcare 8% Industrial 10% Building & Construction 5% Telecommunications 1% LATAM (9% of sales) Transportation 5% All charts reflect 2021 financials Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2024-07/TPE Whitepaper_0.pdf
One answer?
One proven approach is to replace traditional vulcanized rubber materials with thermoplastic elastomers, better known as TPEs.
Because they remove the need to wash products and simplify bonding to rigid substrates, TPEs require only one to two minutes of processing time from start to finish, and are ideal when producing dynamic and static seals, liquid storage and delivery packaging, and infusion therapy devices.